"NGS-Based Viral Safety Testing for ATMPs: Mandatory or Just an Option?"
NGS-based virus testing, a preferred approach to mitigating the virus contamination risk
While advanced therapy medicinal products (ATMPs) represent a promising new generation of treatments, they are more vulnerable to viral contaminations that could go undetected by standard methods compared to well-established biologics such as monoclonal antibodies.
Next-generation sequencing (NGS) is not new but has recently gained more recognition as an advanced technology for viral safety testing of biologics. In this recent article published in BioProcess Journal, learn more about NGS and how it can potentially replace several established testing methods for ATMPs with improved turnaround times and reduced overall costs.
Offered Free by: Charles River Laboratories